In VivoImagine a patient with major depression who has tried three different antidepressants without success. Instead of guessing which medication to try next, their psychiatrist attaches a single EEG electr
ScripA few months after restructuring to conserve cash and put primary focus on its lead candidate BDTX-1535 in first-line non-small cell lung cancer, Black Diamond Therapeutics found a lifeline in Servier
Pink SheetServier was due to appear before the European Medicines Agency this week to explain why its targeted therapy drug vorasidenib, which is in the final stages of regulatory review for treating certain ty
ScripServier Pharmaceuticals CEO David Lee, who oversees the French company’s US business, and chief scientific officer Claude Bertrand were at the J.P. Morgan Healthcare Conference with a purpose: to find